Literature DB >> 25044674

Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

Sergio Davì1, Francesca Minoia, Angela Pistorio, AnnaCarin Horne, Alessandro Consolaro, Silvia Rosina, Francesca Bovis, Rolando Cimaz, Maria Luz Gamir, Norman T Ilowite, Isabelle Kone-Paut, Sheila Knupp Feitosa de Oliveira, Deborah McCurdy, Clovis Artur Silva, Flavio Sztajnbok, Elena Tsitsami, Erbil Unsal, Jennifer E Weiss, Nico Wulffraat, Mario Abinun, Amita Aggarwal, Maria Teresa Apaz, Itziar Astigarraga, Fabrizia Corona, Ruben Cuttica, Gianfranco D'Angelo, Eli M Eisenstein, Soad Hashad, Loredana Lepore, Velma Mulaosmanovic, Susan Nielsen, Sampath Prahalad, Donato Rigante, Valda Stanevicha, Gary Sterba, Gordana Susic, Syuji Takei, Ralf Trauzeddel, Mabruka Zletni, Nicolino Ruperto, Alberto Martini, Randy Q Cron, Angelo Ravelli.   

Abstract

OBJECTIVE: To compare the capacity of the 2004 diagnostic guidelines for hemophagocytic lymphohistiocytosis (HLH-2004) with the capacity of the preliminary diagnostic guidelines for systemic juvenile idiopathic arthritis (JIA)-associated macrophage activation syndrome (MAS) to discriminate MAS complicating systemic JIA from 2 potentially confusable conditions, represented by active systemic JIA without MAS and systemic infection.
METHODS: International pediatric rheumatologists and hemato-oncologists were asked to retrospectively collect clinical information from patients with systemic JIA-associated MAS and confusable conditions. The ability of the guidelines to differentiate MAS from the control diseases was evaluated by calculating the sensitivity and specificity of each set of guidelines and the kappa statistics for concordance with the physician's diagnosis. Owing to the fact that not all patients were assessed for hemophagocytosis on bone marrow aspirates and given the lack of data on natural killer cell activity and soluble CD25 levels, the HLH-2004 guidelines were adapted to enable the diagnosis of MAS when 3 of 5 of the remaining items (3/5-adapted) or 4 of 5 of the remaining items (4/5-adapted) were present.
RESULTS: The study sample included 362 patients with systemic JIA and MAS, 404 patients with active systemic JIA without MAS, and 345 patients with systemic infection. The best capacity to differentiate MAS from systemic JIA without MAS was found when the preliminary MAS guidelines were applied. The 3/5-adapted HLH-2004 guidelines performed better than the 4/5-adapted guidelines in distinguishing MAS from active systemic JIA without MAS. The 3/5-adapted HLH-2004 guidelines and the preliminary MAS guidelines with the addition of ferritin levels ≥500 ng/ml discriminated best between MAS and systemic infections.
CONCLUSION: The preliminary MAS guidelines showed the strongest ability to identify MAS in systemic JIA. The addition of hyperferritinemia enhanced their capacity to differentiate MAS from systemic infections. The HLH-2004 guidelines are likely not appropriate for identification of MAS in children with systemic JIA.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2014        PMID: 25044674     DOI: 10.1002/art.38769

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  32 in total

1.  Editorial: 21st Century Storm Chasers: Defining Macrophage Activation Syndrome.

Authors:  Scott W Canna; Peter A Nigrovic
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

2.  Paediatric rheumatic disease: Diagnosing macrophage activation syndrome in systemic JIA.

Authors:  Sebastiaan J Vastert; Berent J Prakken
Journal:  Nat Rev Rheumatol       Date:  2014-09-09       Impact factor: 20.543

3.  An atypical presentation of adult-onset Still's disease complicated by pulmonary hypertension and macrophage activation syndrome treated with immunosuppression: a case-based review of the literature.

Authors:  Mili V Mehta; Daniel K Manson; Evelyn M Horn; Jennifer Haythe
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

Review 4.  Macrophage activation syndrome in juvenile dermatomyositis: a systematic review.

Authors:  Dimitri Poddighe; Kaisar Dauyey
Journal:  Rheumatol Int       Date:  2019-09-16       Impact factor: 2.631

Review 5.  Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg.

Authors:  Courtney Crayne; Randy Q Cron
Journal:  Eur J Rheumatol       Date:  2019-12-03

Review 6.  Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.

Authors:  Lauren A Henderson; Randy Q Cron
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

Review 7.  Hyperferritinemia and inflammation.

Authors:  Kate F Kernan; Joseph A Carcillo
Journal:  Int Immunol       Date:  2017-11-01       Impact factor: 4.823

8.  Whole-Exome Sequencing Reveals Mutations in Genes Linked to Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome in Fatal Cases of H1N1 Influenza.

Authors:  Grant S Schulert; Mingce Zhang; Ndate Fall; Ammar Husami; Diane Kissell; Andrew Hanosh; Kejian Zhang; Kristina Davis; Jeffrey M Jentzen; Lena Napolitano; Javed Siddiqui; Lauren B Smith; Paul W Harms; Alexei A Grom; Randy Q Cron
Journal:  J Infect Dis       Date:  2015-11-23       Impact factor: 5.226

Review 9.  Hepatic inflammatory pseudotumor presenting in an 8-year-old boy: A case report and review of literature.

Authors:  Hussa Al-Hussaini; Haya Azouz; Ahmed Abu-Zaid
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

Review 10.  Macrophage Activation Syndrome.

Authors:  Ethan S Sen; Sarah L N Clarke; Athimalaipet V Ramanan
Journal:  Indian J Pediatr       Date:  2015-09-24       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.